LIP
EW icon

Liontrust Investment Partners’s Edwards Lifesciences EW Stock Holding History

Liontrust Investment Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110M Buy
1,216,379
+78,008
+7% +$6.53M 1.62% 21
2026
Q1 		$91.2M Sell
1,138,371
-106,010
-9% -$8.74M 1.56% 25
2025
Q4 		$106M Sell
1,244,381
-115,780
-9% -$9.5M 1.57% 18
2025
Q3 		$106M Sell
1,360,161
-72,348
-5% -$5.65M 1.55% 26
2025
Q2 		$112M Sell
1,432,509
-85,643
-6% -$6.39M 1.6% 28
2025
Q1 		$110M Sell
1,518,152
-92,287
-6% -$6.61M 1.72% 23
2024
Q4 		$119M Buy
1,610,439
+402,261
+33% +$28.2M 1.73% 23
2024
Q3 		$112M Hold
1,208,178
– – 1.59% 25
2024
Q2 		$112M Sell
1,208,178
-26,957
-2% -$2.39M 1.59% 25
2024
Q1 		$118M Sell
1,235,135
-41,571
-3% -$3.49M 1.65% 28
2023
Q4 		$97.3M Buy
1,276,706
+1,258,056
+6,746% +$87.5M 1.41% 29
2023
Q3 		$1.29M Buy
+18,650
New +$1.5M 0.02% 156

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Liontrust Investment Partners's EW Position: Q2 2026 in Review

Liontrust Investment Partners increased its Edwards Lifesciences (EW) stake by 6.9% in Q2 2026, buying an estimated $6.53M and bringing the position to 1,216,379 shares worth $110M. The position accounts for 1.62% of the portfolio, ranked #21.

Liontrust Investment Partners first reported a position in EW in Q3 2023 and has held it in 12 quarters since. The position peaked at $119M in Q4 2024. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Liontrust Investment Partners held 1,216,379 shares of Edwards Lifesciences worth $110M as of Q2 2026.
  • Liontrust Investment Partners bought 78,008 Edwards Lifesciences shares in Q2 2026, an estimated $6.53M.
  • Edwards Lifesciences made up 1.62% of Liontrust Investment Partners's portfolio in Q2 2026, its #21 holding.
  • Liontrust Investment Partners first reported a position in Edwards Lifesciences in Q3 2023 and has held it in 12 quarters since.
  • Liontrust Investment Partners's Edwards Lifesciences position peaked at $119M in Q4 2024.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Liontrust Investment Partners's 13F filing for Q2 2026, filed 18 Aug 2026.